logo-loader
Motif Bio PLC

Motif Bio PLC says it is in the advanced stages of concluding a proposed placing to institutional and other investors

It said the net proceeds of the proposed placing, when taken together with its existing cash resources are expected to be sufficient to fund the business beyond its meeting with the US FDA

Cash raising
Motif Bio said: “Whilst there can be no certainty that the Proposed Placing will proceed, nor as to the quantum, pricing, or timing of any such placing the Board is seeking to conclude the process shortly"

Motif Bio PLC (LON:MTFB) (NASDAQ:MTFB) has confirmed that it needs to raise additional capital in the near term and said it is in the advanced stages of concluding a proposed placing of new ordinary shares to institutional and other investors.

The AIM-listed clinical-stage biopharmaceutical company, specialising in developing novel antibiotics, said the net proceeds of the proposed placing, when taken together with its existing cash resources are expected to be sufficient to fund the business beyond its meeting with the US Food & Drug Administration (FDA) scheduled for 3 May 2019.

READ: Motif Bio surges as US FDA agrees to a meeting to discuss new drug application for novel antibiotic iclaprim

At that meeting, Motif Bio will discuss the Complete Response Letter received in respect of the company's New Drug Application (NDA) for its lead novel antibiotic, iclaprim, which said additional data was needed.

The company said it expects to be able to provide guidance as to a route to approval for iclaprim upon receipt of the minutes from this meeting, which would typically be approximately 30 days from the meeting date.

The group added that assuming a viable route to approval, it is expected that further additional funds will be required to resubmit an NDA and reach a new approval date.

Motif Bio concluded: “Whilst there can be no certainty that the Proposed Placing will proceed, nor as to the quantum, pricing, or timing of any such placing the Board is seeking to conclude the process shortly and will update shareholders accordingly.”

In mid-morning trading, Motif Bio shares were 4.6% lower at 7.50p.

Quick facts: Motif Bio PLC

Price: £0.03

Market: AIM
Market Cap: £8.61 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

4 weeks, 1 day ago

2 min read